AU2006277968A1 - Use of tiotropium salts in the treatment of severe persistant asthma - Google Patents

Use of tiotropium salts in the treatment of severe persistant asthma Download PDF

Info

Publication number
AU2006277968A1
AU2006277968A1 AU2006277968A AU2006277968A AU2006277968A1 AU 2006277968 A1 AU2006277968 A1 AU 2006277968A1 AU 2006277968 A AU2006277968 A AU 2006277968A AU 2006277968 A AU2006277968 A AU 2006277968A AU 2006277968 A1 AU2006277968 A1 AU 2006277968A1
Authority
AU
Australia
Prior art keywords
treatment
asthma
tiotropium
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006277968A
Other languages
English (en)
Inventor
Michael Engel
Stefan Heinrichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006277968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2006277968A1 publication Critical patent/AU2006277968A1/en
Priority to AU2012258410A priority Critical patent/AU2012258410B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006277968A 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma Abandoned AU2006277968A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012258410A AU2012258410B2 (en) 2005-08-06 2012-11-28 Use of tiotropium salts in the treatment of severe persistant asthma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107266 2005-08-06
EP05107266.8 2005-08-06
PCT/EP2006/064958 WO2007017438A1 (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012258410A Division AU2012258410B2 (en) 2005-08-06 2012-11-28 Use of tiotropium salts in the treatment of severe persistant asthma

Publications (1)

Publication Number Publication Date
AU2006277968A1 true AU2006277968A1 (en) 2007-02-15

Family

ID=35432680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006277968A Abandoned AU2006277968A1 (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Country Status (16)

Country Link
US (3) US20070032516A1 (enExample)
EP (1) EP1915158A1 (enExample)
JP (1) JP2009504604A (enExample)
KR (1) KR20080039974A (enExample)
CN (1) CN101237872A (enExample)
AR (1) AR055597A1 (enExample)
AU (1) AU2006277968A1 (enExample)
BR (1) BRPI0614394A2 (enExample)
CA (1) CA2617717C (enExample)
IL (1) IL189248A0 (enExample)
MX (1) MX2008001506A (enExample)
NZ (1) NZ566399A (enExample)
RU (1) RU2422144C2 (enExample)
TW (1) TWI409072B (enExample)
WO (1) WO2007017438A1 (enExample)
ZA (1) ZA200800186B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
WO2007077162A1 (en) * 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma
MX2012005711A (es) * 2009-11-17 2012-10-05 Cipla Ltd Soluciones de inhalacion.
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5888396A (en) * 1996-12-17 1999-03-30 Perriello; Felix Anthony Bioremediation of pollutants with butane-utilizing bacteria
US6156503A (en) * 1997-03-03 2000-12-05 The Regents Of The University Of California Diagnosing asthma patients predisposed to adverse β-agonist reactions
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
CA2425539C (en) * 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
WO2007077162A1 (en) 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma

Also Published As

Publication number Publication date
NZ566399A (en) 2011-07-29
CA2617717C (en) 2014-02-11
RU2422144C2 (ru) 2011-06-27
TW200744606A (en) 2007-12-16
US20130245059A1 (en) 2013-09-19
WO2007017438A1 (en) 2007-02-15
CA2617717A1 (en) 2007-02-15
RU2008108302A (ru) 2009-09-20
EP1915158A1 (en) 2008-04-30
ZA200800186B (en) 2009-04-29
IL189248A0 (en) 2008-08-07
KR20080039974A (ko) 2008-05-07
US20070032516A1 (en) 2007-02-08
MX2008001506A (es) 2008-04-07
BRPI0614394A2 (pt) 2011-03-29
AR055597A1 (es) 2007-08-29
TWI409072B (zh) 2013-09-21
JP2009504604A (ja) 2009-02-05
US20090163531A1 (en) 2009-06-25
CN101237872A (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
US20030018019A1 (en) Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20090088408A1 (en) Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
CA2534132C (en) Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026948A1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20150224090A1 (en) Use of tiotropium salts in the treatment of moderate persistent asthma
US20130245059A1 (en) Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma
US20060034776A1 (en) Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics
AU2012258410B2 (en) Use of tiotropium salts in the treatment of severe persistant asthma
MX2008007568A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
US20070072891A1 (en) Method for the Protection Against the Risk of Cardiac Disorders Comprising Administration of Tiotropium Salts
HK1126974A (en) Use of tiotropium salts in the treatment of moderate persistent asthma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted